Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking scientific session at the Vascular Interventional Advances (VIVA) Annual Conference 2016. DANCE is a prospective, multicenter, single-arm study designed to assess the clinical performance of the localized delivery of a generic steroid, dexamethasone, to the tissues around arteries that have been injured during endovascular interventions, using Mercator’s proprietary Bullfrog Micro-Infusion Device.